Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gao takes chair from Chan at China Biologic

This article was originally published in Scrip

Executive Summary

David (Xiaoying) Gao has been elected chairman of the board of directors at China Biologic Products, taking over from Siu Ling Chan who served for more than five years, and who will remain on the board. Mr Gao’s appointment comes as the board adopts a series of measures to improve the company’s corporate governance, enhancing the independence and transparency of the board. These include increasing the size of the board from seven to nine members, with the intention of appointing two new independent directors. Mr Gao joined the board of directors in October 2011. China Biologic operates through subsidiaries in China as a major plasma-based biopharmaceutical company in that market. Mr Gao was previously CEO and director of BMP Sunstone, which was acquired by Sanofi last year. He was also chairman of Beijing Med-Pharm from 2002 to 2004. The company has also appointed Ming Yang as vice-president, finance and compliance and treasurer.

You may also be interested in...



Gaming Whiz Brings AI Smarts To Drug Discovery

GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.

The Top 10 Best-Selling Drugs of 2019

INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market. 

Interview: Why Biotech Companies Should Be Confident About Deals Despite Coronavirus

Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.

Topics

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel